{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:17:31Z","timestamp":1718169451986},"reference-count":73,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.ejca.2009.05.002","type":"journal-article","created":{"date-parts":[[2009,6,4]],"date-time":"2009-06-04T04:52:32Z","timestamp":1244091152000},"page":"2266-2273","source":"Crossref","is-referenced-by-count":15,"title":["Immunotherapy for malignant melanoma \u2013 Tracing Ariadne\u2019s thread through the labyrinth"],"prefix":"10.1016","volume":"45","author":[{"given":"John M.","family":"Grange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Krone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.05.002_bib1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4065\/82.3.364","article-title":"Malignant melanoma in the 21st century, part 1, epidemiology, risk factors, screening, prevention, and diagnosis","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2009.05.002_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","article-title":"Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update","volume":"13","author":"Ishihara","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.05.002_bib3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/annonc\/mdm087","article-title":"Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands","volume":"18","author":"de Vries","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2009.05.002_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.2005.06386.x","article-title":"Predictions of skin cancer incidence in the Netherlands up to 2015","volume":"152","author":"de Vries","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2009.05.002_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.ejca.2009.05.002_bib7","first-page":"568","article-title":"Does the sun play a role in the aetiology of malignant melanoma? A review","volume":"97","author":"Isaacson","year":"2007","journal-title":"S Afr Med J"},{"key":"10.1016\/j.ejca.2009.05.002_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/978-0-387-77574-6_9","article-title":"Ultraviolet radiation and malignant melanoma","volume":"624","author":"Moan","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ejca.2009.05.002_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CEJ.0b013e3282b6fceb","article-title":"A reduced repair efficiency can explain increasing melanoma rates","volume":"17","author":"Hallberg","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ejca.2009.05.002_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2004.08.010","article-title":"Protection against melanoma by vaccination with Bacille Calmette\u2013Gu\u00e9rin (BCG) and\/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control","volume":"41","author":"Krone","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1258\/jrsm.95.6.296","article-title":"Campbell De Morgan\u2019s \u2018Observations on cancer\u2019, and their relevance today","volume":"95","author":"Grange","year":"2002","journal-title":"J R Soc Med"},{"key":"10.1016\/j.ejca.2009.05.002_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/978-1-4684-5766-7_52","article-title":"Coley\u2019s toxins\u2013the first century","volume":"267","author":"Nauts","year":"1990","journal-title":"Adv Exp Biol Med"},{"key":"10.1016\/j.ejca.2009.05.002_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00008390-199910000-00011","article-title":"Infections and melanoma risk: results of a multicentre EORTC case-control study","volume":"9","author":"K\u00f6lmel","year":"1999","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1523-1747.2002.00643.x","article-title":"Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study","volume":"119","author":"Pfahlberg","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2009.05.002_bib15","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0959-8049(03)00625-7","article-title":"Impact of vaccinations and infectious diseases on melanoma risk\u2013evaluation of an EORTC case-control study","volume":"39","author":"Krone","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.vaccine.2008.10.076","article-title":"Does yellow fever 17D vaccine protect against melanoma?","volume":"27","author":"Mastrangelo","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2009.05.002_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2004.09.023","article-title":"Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients","volume":"41","author":"K\u00f6lmel","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib18","first-page":"5510","article-title":"A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes","volume":"62","author":"Schiavetti","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/intimm\/dxn066","article-title":"Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor","volume":"20","author":"Voelter","year":"2008","journal-title":"Int Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejca.2009.05.002_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0301-0546(08)75868-3","article-title":"Toll-like receptors: a family of innate sensors of danger that alert and drive immunity","volume":"36","author":"Montero Vega","year":"2008","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.ejca.2009.05.002_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1189\/jlb.1003482","article-title":"Controlling the Toll road to dendritic cell polarization","volume":"75","author":"Mazzoni","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ejca.2009.05.002_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaci.2006.03.003","article-title":"Review","volume":"117","author":"Schaub","year":"2006","journal-title":"The many faces of the hygiene hypothesis. J Allergy Clin Immunol"},{"issue":"Part 2","key":"10.1016\/j.ejca.2009.05.002_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3184\/003685001783239014","article-title":"Environmental echoes","volume":"84","author":"Stanford","year":"2001","journal-title":"Sci Progr"},{"key":"10.1016\/j.ejca.2009.05.002_bib25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.bjc.6600091","article-title":"Day-care, early common infections and childhood acute leukaemia: a multicenter French case-control study","volume":"86","author":"Perrillat","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib26","doi-asserted-by":"crossref","unstructured":"Krone B, Oeffner F, Grange JM. Is the risk of multiple sclerosis related to the \u2018biography\u2019 of the immune system? J Neurol 2009; Mar 1. [Epub ahead of print].","DOI":"10.1007\/s00415-009-5068-8"},{"key":"10.1016\/j.ejca.2009.05.002_bib27","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.4049\/jimmunol.178.7.4112","article-title":"Four functionally distinct populations of human effector-memory CD8+ T lymphocytes","volume":"178","author":"Romero","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib28","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.4049\/jimmunol.171.10.5454","article-title":"Increased CD8+ T cell memory to concurrent infection at the expense of increased erosion of pre-existing memory: the paradoxical role of IL-15","volume":"171","author":"Chapdelaine","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nri2189","article-title":"Regulatory T cells and infection: a dangerous necessity","volume":"7","author":"Belkaid","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib30","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","article-title":"Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment","volume":"13","author":"Gajewski","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib31","doi-asserted-by":"crossref","first-page":"20884","DOI":"10.1073\/pnas.0710557105","article-title":"Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma","volume":"104","author":"Vence","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.05.002_bib32","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-06-0944","article-title":"Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms","volume":"12","author":"Liz\u00e9e","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1128\/CMR.16.4.637-646.2003","article-title":"Role of Toll-like receptors in pathogen recognition","volume":"16","author":"Janssens","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ejca.2009.05.002_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature06246","article-title":"Recognition of microorganisms and activation of the immune response","volume":"449","author":"Medzhitov","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2009.05.002_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0041-3879(91)90049-X","article-title":"Mobilising the appropriate T-cell subset: the immune response as taxonomist?","volume":"72","author":"Rook","year":"1991","journal-title":"Tubercle"},{"key":"10.1016\/j.ejca.2009.05.002_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1615\/CritRevImmunol.v28.i2.10","article-title":"Pathogen associated molecular pattern in cancer immunotherapy","volume":"28","author":"Hobohm","year":"2008","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib37","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1016\/j.vaccine.2008.06.092","article-title":"The use of mycobacterial adjuvant-based agents for immunotherapy of cancer","volume":"26","author":"Grange","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2009.05.002_bib38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ni1059","article-title":"Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance","volume":"5","author":"Yang","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib39","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-07-1378","article-title":"Toll-like receptors in tumor immunotherapy","volume":"13","author":"Paulos","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ejca.2009.05.002_bib41","first-page":"8218","article-title":"Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells","volume":"61","author":"Pietra","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib42","first-page":"4446","article-title":"Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis","volume":"60","author":"Jenne","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jlb.67.4.508","article-title":"The interleukin-1\/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products","volume":"67","author":"Bowie","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ejca.2009.05.002_bib44","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1084\/jem.20070021","article-title":"Tumoricidal activity of TLR7\/8-activated inflammatory dendritic cells","volume":"204","author":"Stary","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2009.05.002_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-4615-1267-7_24","article-title":"Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines","volume":"491","author":"Hakomori","year":"2001","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ejca.2009.05.002_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.0022-202X.2004.23515.x","article-title":"Epitope-specific antibody response to Mel-CAM induced by mimotope immunization","volume":"124","author":"Hafner","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2009.05.002_bib47","doi-asserted-by":"crossref","first-page":"B4","DOI":"10.1016\/j.vaccine.2007.06.033","article-title":"Vaccine therapy for melanoma: current status and future directions","volume":"25","author":"Terando","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2009.05.002_bib48","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.4049\/jimmunol.168.8.4231","article-title":"Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity","volume":"168","author":"Valmori","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib49","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1172\/JCI118958","article-title":"Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1\/Melan-A antigen","volume":"98","author":"Maeurer","year":"1996","journal-title":"J Clin Invest"},{"issue":"Mar 4","key":"10.1016\/j.ejca.2009.05.002_bib50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1477-7819-6-30","article-title":"Extensive necrosis of visceral melanoma metastases after immunotherapy","volume":"6","author":"Stoeter","year":"2008","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejca.2009.05.002_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2133.2008.08709.x","article-title":"Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1\/Th2 balance in patients with metastatic melanoma","volume":"159","author":"Green","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2009.05.002_bib52","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-08-1980","article-title":"Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma","volume":"15","author":"Nevala","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib53","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1073\/pnas.0710929105","article-title":"Effective tumor treatment targeting a melanoma\/melanocyte-associated antigen triggers severe ocular autoimmunity","volume":"105","author":"Palmer","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.05.002_bib54","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","volume":"140","author":"Gilliet","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2009.05.002_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1574-695X.1998.tb01151.x","article-title":"Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis","volume":"21","author":"Lehrer","year":"1998","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.ejca.2009.05.002_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ejca.2009.05.002_bib57","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.05.002_bib58","first-page":"97","article-title":"Cancer and tuberculosis","volume":"9","author":"Pearl","year":"1929","journal-title":"Am J Hyg"},{"key":"10.1016\/j.ejca.2009.05.002_bib59","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1524-4725.1993.tb00989.x","article-title":"Pooled analysis of the efficacy of bacille Calmette\u2013Gu\u00e9rin (BCG) immunotherapy in malignant melanoma","volume":"19","author":"Tan","year":"1993","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.ejca.2009.05.002_bib60","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(197904)43:4<1314::AID-CNCR2820430420>3.0.CO;2-6","article-title":"Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS)","volume":"43","author":"Yamamura","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib61","first-page":"3262","article-title":"Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette\u2013Guerin","volume":"39","author":"Yasumoto","year":"1979","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.002_bib62","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette\u2013Gu\u00e9rin in patients with superficial bladder cancer. Swedish\u2013Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2009.05.002_bib63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0025-7125(16)31889-2","article-title":"Intralesional immunotherapy of melanoma with BCG","volume":"60","author":"Rosenberg","year":"1976","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ejca.2009.05.002_bib64","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0140-6736(95)92542-2","article-title":"Tuberculosis and cancer: parallels in host responses and therapeutic approaches?","volume":"345","author":"Grange","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.05.002_bib65","first-page":"191","article-title":"Therapeutic vaccination for cancer: the potential value of mycobacterial products","volume":"12","author":"Stanford","year":"1999","journal-title":"Int J Pharmaceut Med"},{"key":"10.1016\/j.ejca.2009.05.002_bib66","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.rmed.2005.09.026","article-title":"Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis","volume":"100","author":"Dlugovitzky","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.ejca.2009.05.002_bib67","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2007.08.021","article-title":"Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung","volume":"44","author":"Stanford","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2007.11.003","article-title":"An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer","volume":"44","author":"Patel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib69","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdh220","article-title":"SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2009.05.002_bib70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lungcan.2004.08.013","article-title":"Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control","volume":"47","author":"Harper-Wynne","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2009.05.002_bib71","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1046\/j.1464-410X.1998.00803.x","article-title":"Immunotherapy of advanced prostate cancer: a phase I\/II trial using Mycobacterium vaccae (SRL 172)","volume":"8","author":"Hrouda","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.ejca.2009.05.002_bib72","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1023\/A:1008307821189","article-title":"Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood leucocytes","volume":"10","author":"Maraveyas","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2009.05.002_bib73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00008390-200308000-00008","article-title":"A randomized phase II trial of SRL172 (Mycobacterium vaccae) +\/\u2212 low-dose interleukin-2 in the treatment of metastatic malignant melanoma","volume":"13","author":"Nicholson","year":"2003","journal-title":"Melanoma Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T12:40:35Z","timestamp":1558356035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909003426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":73,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0959804909003426"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.05.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}